|
1
|
Cohen PA, Jhingran A, Oaknin A and Denny
L: Cervical cancer. Lancet. 393:169–182. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li H, Wu X and Cheng X: Advances in
diagnosis and treatment of metastatic cervical cancer. J Gynecol
Oncol. 27:e432016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang H, Zhao Y, Chen M and Cui J:
Identification of novel long non-coding and circular RNAs in human
papillomavirus-mediated cervical cancer. Front Microbiol.
8:17202017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Choi YJ and Park JS: Clinical significance
of human papillomavirus genotyping. J Gynecol Oncol. 27:e212016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stanley MA: Epithelial cell responses to
infection with human papillomavirus. Clin Microbiol Rev.
25:215–222. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hong S, Mehta KP and Laimins LA:
Suppression of STAT-1 expression by human papillomaviruses is
necessary for differentiation-dependent genome amplification and
plasmid maintenance. J Virol. 85:9486–9494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li X, Tian R, Gao H, Yang Y, Williams BRG,
Gantier MP, McMillan NAJ, Xu D, Hu Y and Gao Y: Identification of a
histone family gene signature for predicting the prognosis of
cervical cancer patients. Sci Rep. 7:164952017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brant AC, Menezes AN, Felix SP, de Almeida
LM, Sammeth M and Moreira MAM: Characterization of HPV integration,
viral gene expression and E6E7 alternative transcripts by RNA-Seq:
A descriptive study in invasive cervical cancer. Genomics.
111:1853–1861. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gong Z, Liu J, Xie X, Xu X, Wu P, Li H,
Wang Y, Li W and Xiong J: Identification of potential target genes
of USP22 via ChIP-seq and RNA-seq analysis in HeLa cells. Genet Mol
Biol. 41:488–495. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu B, Chen L, Zhang W, Li Y, Zhang Y, Gao
Y, Teng X, Zou L, Wang Q, Jia H, et al: TOP2A and CENPF are
synergistic master regulators activated in cervical cancer. BMC Med
Genomics. 13:1452020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu YP, Wang ZQ, Liang XD, Wang Y and Wang
JL: Comparative analysis of the prognosis of patients with locally
advanced cervical cancer undergoing laparoscopic or abdominal
surgery. Zhonghua Fu Chan Ke Za Zhi. 55:609–616. 2020.(In Chinese).
PubMed/NCBI
|
|
12
|
Berek JS, Matsuo K, Grubbs BH, Gaffney DK,
Lee SI, Kilcoyne A, Cheon GJ, Yoo CW, Li L, Shao Y, et al:
Multidisciplinary perspectives on newly revised 2018 FIGO staging
of cancer of the cervix uteri. J Gynecol Oncol. 30:e402019.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Anaya J: OncoLnc: Linking TCGA survival
data to mRNAs, miRNAs, and lncRNAs. PeerJ Comput Sci. 2:e672016.
View Article : Google Scholar
|
|
15
|
Durfee LA, Lyon N, Seo K and Huibregtse
JM: The ISG15 conjugation system broadly targets newly synthesized
proteins: Implications for the antiviral function of ISG15. Mol
Cell. 38:722–732. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cannella F, Scagnolari C, Selvaggi C,
Stentella P, Recine N, Antonelli G and Pierangeli A: Interferon
lambda 1 expression in cervical cells differs between low-risk and
high-risk human papillomavirus-positive women. Med Microbiol
Immunol. 203:177–184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pierangeli A, Degener AM, Ferreri ML, Riva
E, Rizzo B, Turriziani O, Luciani S, Scagnolari C and Antonelli G:
Interferon-induced gene expression in cervical mucosa during human
papillomavirus infection. Int J Immunopathol Pharmacol. 24:217–223.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rajkumar T, Sabitha K, Vijayalakshmi N,
Shirley S, Bose MV, Gopal G and Selvaluxmy G: Identification and
validation of genes involved in cervical tumourigenesis. BMC
Cancer. 11:802011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Desai SD, Reed RE, Burks J, Wood LM,
Pullikuth AK, Haas AL, Liu LF, Breslin JW, Meiners S and Sankar S:
ISG15 disrupts cytoskeletal architecture and promotes motility in
human breast cancer cells. Exp Biol Med (Maywood). 237:38–49. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kiessling A, Hogrefe C, Erb S, Bobach C,
Fuessel S, Wessjohann L and Seliger B: Expression, regulation and
function of the ISGylation system in prostate cancer. Oncogene.
28:2606–2620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li C, Wang J, Zhang H, Zhu M, Chen F, Hu
Y, Liu H and Zhu H: Interferon-stimulated gene 15 (ISG15) is a
trigger for tumorigenesis and metastasis of hepatocellular
carcinoma. Oncotarget. 5:8429–8441. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wood LM, Pan ZK, Seavey MM, Muthukumaran G
and Paterson Y: The ubiquitin-like protein, ISG15, is a novel
tumor-associated antigen for cancer immunotherapy. Cancer Immunol
Immunother. 61:689–700. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Swaim CD, Scott AF, Canadeo LA and
Huibregtse JM: Extracellular ISG15 signals cytokine secretion
through the LFA-1 integrin receptor. Mol Cell. 68:581–590.e5. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
D'Cunha J, Knight E Jr, Haas AL, Truitt RL
and Borden EC: Immunoregulatory properties of ISG15, an
interferon-induced cytokine. Proc Natl Acad Sci USA. 93:211–215.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Forys JT, Kuzmicki CE, Saporita AJ,
Winkeler CL, Maggi LB Jr and Weber JD: ARF and p53 coordinate tumor
suppression of an oncogenic IFN-β-STAT1-ISG15 signaling axis. Cell
Rep. 7:514–526. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hadjivasiliou A: ISG15 implicated in
cytoskeleton disruption and promotion of breast cancer. Expert Rev
Proteomics. 9:72012.
|
|
27
|
Cerikan B and Schiebel E: DOCK6
inactivation highlights ISGylation as RHO-GTPase balancer. Cell
Cycle. 16:304–305. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Burks J, Reed RE and Desai SD: ISGylation
governs the oncogenic function of Ki-Ras in breast cancer.
Oncogene. 33:794–803. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qiu X, Hong Y, Yang D, Xia M, Zhu H, Li Q,
Xie H, Wu Q, Liu C and Zuo C: ISG15 as a novel prognostic biomarker
for hepatitis B virus-related hepatocellular carcinoma. Int J Clin
Exp Med. 8:17140–17150. 2015.PubMed/NCBI
|
|
30
|
Yan W, Shih JH, Rodriguez-Canales J,
Tangrea MA, Ylaya K, Hipp J, Player A, Hu N, Goldstein AM, Taylor
PR, et al: Identification of unique expression signatures and
therapeutic targets in esophageal squamous cell carcinoma. BMC Res
Notes. 5:732012. View Article : Google Scholar : PubMed/NCBI
|
